{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:44:37Z","timestamp":1794487477192,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eclinm.2025.103184","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:22:22Z","timestamp":1743985342000},"page":"103184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial"],"prefix":"10.1016","volume":"82","author":[{"given":"FangJie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaQuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuMing","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShiHong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"SiTu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengRu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaoTing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PengXin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShiYang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShaoHan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChuanMiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-6668","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2025.103184_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103184_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chinese Med J"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103184_bib3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus","volume":"326","author":"Herskovic","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103184_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103184_bib5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.eclinm.2025.103184_bib6","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.2014.56.7156","article-title":"Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer","volume":"32","author":"Sudo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103184_bib7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.radonc.2017.06.019","article-title":"The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy","volume":"124","author":"Xi","year":"2017","journal-title":"Radiother Oncol"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103184_bib8","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103184_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0120","article-title":"Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: a randomized clinical trial","volume":"5","author":"Ai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103184_bib10","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.23.02009","article-title":"Capecitabine or capecitabine plus oxaliplatin versus fluorouracil plus cisplatin in definitive concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (CRTCOESC): a multicenter, randomized, open-label, phase 3 trial","volume":"42","author":"Jia","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103184_bib11","article-title":"Moderately hypo-fractionated radiotherapy combined with S-1 in inoperable locally advanced esophageal squamous cell carcinoma: a prospective, single-arm phase II study (GASTO-1045)","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2025.103184_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760631","article-title":"A\u00a0prospective phase II study of simultaneous modulated accelerated radiotherapy concurrently with CDDP\/S1 for esophageal squamous cell carcinoma in the elderly","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103184_bib13","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","article-title":"A\u00a0phase III multicenter randomized clinical trial of 60Gy versus 50Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103184_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103184_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-29223-1","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103184_bib16","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.eclinm.2025.103184_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","author":"Qin","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103184_bib18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs Placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103184_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103184_bib20","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1038\/s41467-021-24288-1","article-title":"Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103184_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237114","article-title":"Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy","volume":"15","author":"Lin","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103184_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doy043","article-title":"A\u00a0new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy","volume":"31","author":"Chen","year":"2018","journal-title":"Dis Esophagus"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103184_bib23","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","article-title":"The reciprocity between radiotherapy and cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103184_bib24","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1007\/s00330-023-09922-4","article-title":"Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET\/CT with postoperative pathology","volume":"33","author":"Cheng","year":"2023","journal-title":"Eur Radiol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103184_bib25","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2019.04.004","article-title":"Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis","volume":"14","author":"de Gouw","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103184_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133690","article-title":"18F-FDG PET-CT after neoadjuvant chemoradiotherapy in esophageal cancer patients to optimize surgical decision making","volume":"10","author":"Anderegg","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103184_bib27","first-page":"3693","article-title":"Risk factors associated with esophageal fistula after radiotherapy for esophageal squamous cell carcinoma","volume":"11","author":"Hu","year":"2020","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.eclinm.2025.103184_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.radonc.2021.02.031","article-title":"High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: a retrospective analysis","volume":"158","author":"Chen","year":"2021","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103184_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10388-021-00860-y","article-title":"Modeling the risk of radiation pneumonitis in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy","volume":"18","author":"Lan","year":"2021","journal-title":"Esophagus"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103184_bib30","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.34176","article-title":"Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"128","author":"Park","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103184_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103184_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205168","article-title":"Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103184_bib33","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103184_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102471","article-title":"Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial","volume":"69","author":"Ai","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103184_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.eclinm.2025.103184_bib36","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103184_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103184_bib38","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/oncolo\/oyab011","article-title":"Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma","volume":"27","author":"He","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103184_bib39","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.eclinm.2025.103184_bib40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:44:06Z","timestamp":1786135446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":40,"alternative-id":["S2589537025001166"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103184","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103184"}}